STAAR Surgical is trading 5.12% down at $22.22, despite the broader market advancing on September 11, 2026; no reliable source identified a fresh company-specific catalyst directly explaining the decline.
- The stock is underperforming the S&P 500, Nasdaq, and Dow, each up roughly 1%.
- Recent coverage includes David Bailey’s September 8 appointment and a September 10 global refractive-surgery report.
- Neither development was explicitly tied to today’s weakness.